CompanyGraph
At a glance
- Depends onMidstream position: 5 outgoing, 6 incoming connections
- ScaleMarket cap is $1.56B, above the global median of $1.18B
- FinancialsAltman Z-Score 3.27: safe zone
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
1.38BEUR1.56B · vs all stocks (USD)
Revenue (TTM)
3.22BEUR3.66B · vs all stocks (USD)
Profit Margin
-1.31%vs Pharmaceutical Retailers peers
Beta
1.42xvs all stocks
52-Week Change
-6.77%vs all stocks
Market Capitalization
1.38BEUR1.56B · vs all stocks (USD)
Enterprise Value
1.50BEUR1.70B · vs all stocks (USD)
Forward P/E
49.45xvs Pharmaceutical Retailers peers
Price to Sales (TTM)
0.3795xvs Pharmaceutical Retailers peers
Price to Book (MRQ)
2.72xvs Pharmaceutical Retailers peers
Enterprise to Revenue
0.4660xvs Pharmaceutical Retailers peers
Enterprise to EBITDA
79.71xvs Pharmaceutical Retailers peers
Gross Margin
22.10%vs Pharmaceutical Retailers peers
Profit Margin
-1.31%vs Pharmaceutical Retailers peers
Operating Margin
1.43%vs Pharmaceutical Retailers peers
Return on Assets (TTM)
-0.16%vs Pharmaceutical Retailers peers
Return on Equity (TTM)
-8.67%vs Pharmaceutical Retailers peers
Revenue (TTM)
3.22BEUR3.66B · vs all stocks (USD)
Revenue per Share (TTM)
159.97EURUpdated Sep 29, 2026Quarterly Revenue Growth
20.30%vs Pharmaceutical Retailers peers
Gross Profit (TTM)
693.70MEUR788.24M · vs all stocks (USD)
EBITDA (TTM)
48.10MEUR54.66M · vs all stocks (USD)
Net Income (TTM)
-42.00MEUR-47.72M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-49.50%vs Pharmaceutical Retailers peers
Operating Cash Flow (TTM)
-5.70MEUR-6.48M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-115.86MEUR-131.65M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.00EURUpdated Sep 29, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Pharmaceutical Retailers peers
Minority Interest (Equity)
20.00MEURFY2025 · Dec 31, 2025Revenue
2.94BEURFY2025 · Dec 31, 2025Cost of Goods Sold
2.28BEURFY2025 · Dec 31, 2025Gross Profit
663.10MEURFY2025 · Dec 31, 2025Operating Income
-29.80MEUR-33.86M · vs all stocks (USD)
Pre-tax Income
-47.70MEURFY2025 · Dec 31, 2025Income Tax Expense
-8.30MEURFY2025 · Dec 31, 2025Net Income
-39.40MEURFY2025 · Dec 31, 2025EBIT
-27.80MEURFY2025 · Dec 31, 2025EBITDA (Income Statement)
48.10MEURFY2025 · Dec 31, 2025Selling, General & Administrative
427.10MEURFY2025 · Dec 31, 2025Other Operating Expenses
1.30MEURFY2025 · Dec 31, 2025Non-operating Interest Income
4.40MEURFY2025 · Dec 31, 2025Non-operating Interest Expense
19.90MEURFY2025 · Dec 31, 2025EPS (Basic)
-1.87EURFY2025 · Dec 31, 2025EPS (Diluted)
-1.87EURFY2025 · Dec 31, 2025Basic Shares Outstanding
20.11MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
20.11MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-28.50MEURFY2025 · Dec 31, 2025Minority Interests (P&L)
1.70MEURFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00EURFY2025 · Dec 31, 2025Operating Cash Flow
-113.20MEURFY2025 · Dec 31, 2025Free Cash Flow
-192.50MEURFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
92.40MEURFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-28.50MEURFY2025 · Dec 31, 2025Stock-based Compensation
3.50MEURFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-18.90MEURFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-69.30MEURFY2025 · Dec 31, 2025Capital Expenditures
-79.30MEURFY2025 · Dec 31, 2025Net Intangibles (CF)
-39.30MEURFY2025 · Dec 31, 2025Net Acquisitions
0.00EURFY2025 · Dec 31, 2025Purchase of Investments
-32.80MEURFY2025 · Dec 31, 2025Sale of Investments
0.00EURFY2025 · Dec 31, 2025Net Investing Cash Flow
-112.10MEURFY2025 · Dec 31, 2025Long-term Debt Issuance
296.30MEURFY2025 · Dec 31, 2025Long-term Debt Payments
-158.70MEURFY2025 · Dec 31, 2025Net Financing Cash Flow
138.00MEURFY2025 · Dec 31, 2025Shares Outstanding
20.18MSharesUpdated Sep 29, 2026Float Shares
14.60MSharesUpdated Sep 29, 2026% Held by Insiders
18.70%vs all stocks
% Held by Institutions
37.00%vs all stocks
Total Cash (MRQ)
118.90MEUR135.10M · vs all stocks (USD)
Total Cash per Share (MRQ)
5.78EURUpdated Sep 29, 2026Total Debt (MRQ)
354.70MEUR403.04M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.7466xvs Pharmaceutical Retailers peers
Current Ratio (MRQ)
1.58xvs Pharmaceutical Retailers peers
Book Value per Share (MRQ)
22.22EURUpdated Sep 29, 2026Total Assets
1.21BEUR1.38B · vs all stocks (USD)
Total Current Assets
619.40MEURFY2025 · Dec 31, 2025Total Liabilities
735.10MEURFY2025 · Dec 31, 2025Total Non-current Assets
594.90MEURFY2025 · Dec 31, 2025Total Non-current Liabilities
335.10MEURFY2025 · Dec 31, 2025Total Current Liabilities
400.00MEURFY2025 · Dec 31, 2025Cash
92.10MEURFY2025 · Dec 31, 2025Cash & Cash Equivalents
92.10MEURFY2025 · Dec 31, 2025Other Short-term Investments
111.10MEURFY2025 · Dec 31, 2025Accounts Receivable
129.50MEURFY2025 · Dec 31, 2025Inventory
214.00MEURFY2025 · Dec 31, 2025Accounts Payable
248.00MEURFY2025 · Dec 31, 2025Short-term Debt
86.30MEURFY2025 · Dec 31, 2025Long-term Debt
329.30MEURFY2025 · Dec 31, 2025Common Stock (Book)
400.00KEURFY2025 · Dec 31, 2025Retained Earnings
-358.20MEURFY2025 · Dec 31, 2025Total Shareholders' Equity
479.20MEUR544.51M · vs all stocks (USD)
52-Week Low
30.20EURUpdated Sep 29, 202652-Week High
90.10EURUpdated Sep 29, 202652-Week Change
-6.77%vs all stocks
Beta
1.42xvs all stocks
50-Day MA
61.65EURUpdated Sep 29, 2026200-Day MA
56.34EURUpdated Sep 29, 2026Avg 10-Day Volume
90.49KSharesUpdated Sep 29, 2026Avg 30-Day Volume
80.03KSharesUpdated Sep 29, 2026Diluted EPS (TTM)
-2.09EURUpdated Sep 29, 20261 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsWhere is this company structurally exposed?
Ulcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
It sits well below its peak, and the fall has been both deep and long.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 3.27: safe zoneNotable
Altman Z-Score: 3.27
Supply Chain
Midstream position: 5 outgoing, 6 incoming connectionsNotable
Outgoing: 5.00Incoming: 6.00
High connectivity hub: 11 industry connectionsNotable
Total Connections: 11.00
Scale
Market cap is $1.56B, above the global median of $1.18BNotable
Market cap (USD): 1,563,784,831.056Global Median: 1,180,223,658.953
Revenue is $3.66B, above the global median of $548.88MNotable
Revenue (USD): 3,655,867,344.722Global Median: 548,883,780.48
Companies that share the same coordination system — how they create, deliver, or capture value.
Ingles Markets Inc.
Tier 1FlowUnit ReplicationInterfaceProduction
Sally Beauty Holdings Inc.
Tier 1FlowUnit ReplicationInterfaceSenseMaking
Com7 Public Company Limited
Tier 1FlowUnit ReplicationInterfaceAttention
Eternal Asia Supply Chain Co., Ltd.
Tier 1FlowUnit ReplicationProductionSenseMaking
Max Stock Ltd.
Tier 1FlowUnit ReplicationProductionInterface
Laobaixing Pharmacy Chain Co., Ltd.
Tier 1FlowUnit ReplicationInterfaceRule
Winmark Corporation
Tier 1FlowUnit ReplicationProductionInterface
Savers Value Village Inc.
Tier 1FlowUnit ReplicationInterfaceProduction
E-Mart Inc.
Tier 1FlowUnit ReplicationInterfaceProduction
BGF Retail Co. Ltd.
Tier 1FlowUnit ReplicationInterfaceProduction
Companies that share active interpretations — structural patterns currently present in both stocks.
United Aircraft Corporation P.J.S.C.
1 interpretationUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
Wanbangde Pharmaceutical Co., Ltd.
1 interpretationUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
Aishida Co., Ltd.
1 interpretationUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated